Floatz Rating
B62/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06188520CT.gov A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05872204CT.gov Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer | — | Recruiting | — | — | — |
NCT04633239CT.gov Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Serous Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Abemaciclib (this asset) | AstraZeneca | P2 | B · 62 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Letrozole | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Olaparib | Institute of Cancer Research, United Kingdom | P3 | BB |
| Defactinib | Verastem, Inc. | P3 | BB |
| Cediranib | National Cancer Institute (NCI) | P2/3 | BB |
| Avutometinib | Verastem, Inc. | P3 | BB |
+42 more in the Ovarian Serous Adenocarcinoma cohort
Other indications for Abemaciclib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Estrogen-Receptor Positive Breast Cancer | — | P3 | BB · 70 |
| Metastatic Neoplasm | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Abemaciclib in Ovarian Serous Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/abemaciclib-ovarian-serous-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →